1)Bostan E, et al:Diagnostic role of direct immunofluorescence assay in determining the etiology of erythroderma;Experience in a tertiary referral hospital. Dermatol Pract Concept 12:e2022160, 2022
2)Miyashiro D, et al:Erythroderma;A prospective study of 309 patients followed for 12 years in teriary center. Sci Rep 10:9774, 2020
3)日本皮膚科学会,他:アトピー性皮膚炎診療ガイドライン2021.日皮会誌131:2691-2777, 2021
4)日本皮膚科学会,他:アトピー性皮膚炎診療ガイドライン2018.日皮会誌128:2431-2502, 2018
5)Murota H, et al:Exacerbating factors and disease burden in patients with atopic dermatitis. Allergol Int 71:25-30, 2022
6)青木敏之,他:アトピー性皮膚炎発症要因調査の試み.日臨皮医誌24:238-244, 2007
7)Miyagaki T, et al:Serum soluble CD26 levels;Diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels. J Eur Acad Dermatol Venereol 27:19-24, 2013
8)Scala E, et al:Specific IgE toward allergenic molecules is a new prognostic marker in patients with Sézary syndrome. Int Arch Allergy Immunol 157:159-167, 2012
9)Kong H, et al:Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 22:850-859, 2012
10)Murota H, et al:Sweat in the pathogenesis of atopic dermatitis. Allergol Int 67:455-459, 2018